Satraplatin in the treatment of hormone-refractory prostate cancer

被引:27
作者
Sternberg, CN
机构
[1] San Camillo Hosp, Dept Med Oncol, I-00152 Rome, Italy
[2] Forlanini Hosp, Dept Med Oncol, I-00152 Rome, Italy
关键词
D O I
10.1111/j.1464-410X.2005.05799.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
[No abstract available]
引用
收藏
页码:990 / 994
页数:5
相关论文
共 22 条
[1]  
*AM CANC SOC, 2005, CANC FACTS FIG 2005, P12
[2]   Combined effects of the orally active cisplatin analog, JM216, and radiation in antitumor therapy [J].
Amorino, GP ;
Mohr, PJ ;
Hercules, SK ;
Pyo, H ;
Choy, H .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 46 (05) :423-426
[3]   Novel therapeutic strategies for androgen-independent prostate cancer: An update [J].
Assikis, VJ ;
Simons, JW .
SEMINARS IN ONCOLOGY, 2004, 31 (02) :26-32
[4]   Phase I study of oral JM216 given twice daily [J].
Beale, P ;
Raynaud, F ;
Hanwell, J ;
Berry, C ;
Moore, S ;
Odell, D ;
Judson, I .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 42 (02) :142-148
[5]  
EISENBERGER MA, 2004, P AM SOC CLIN ONCOL, V23
[6]  
KELLAND LR, 1993, CANCER RES, V53, P2581
[7]   An update on satraplatin: the first orally available platinum anticancer drug [J].
Kelland, LR .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (06) :1373-1382
[8]   Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum (JM216) administered once a day for five consecutive days: A phase I study [J].
Kurata, T ;
Tamura, T ;
Sasaki, Y ;
Fujii, H ;
Negoro, S ;
Fukuoka, M ;
Saijo, N .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2000, 30 (09) :377-384
[9]   A PHASE-I AND PHARMACOLOGY STUDY OF AN ORAL PLATINUM COMPLEX, JM216 - DOSE-DEPENDENT PHARMACOKINETICS WITH SINGLE-DOSE ADMINISTRATION [J].
MCKEAGE, MJ ;
MISTRY, P ;
WARD, J ;
BOXALL, FE ;
LOH, S ;
ONEILL, C ;
ELLIS, P ;
KELLAND, LR ;
MORGAN, SE ;
MURRER, B ;
SANTABARBARA, P ;
HARRAP, KR ;
JUDSON, IR .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1995, 36 (06) :451-458
[10]  
MCKEAGE MJ, 1994, CANCER RES, V54, P4118